Recent progress in the field of antibacterial pristinamycins

Current Medicinal Chemistry: Anti-Infective Agents

Volumn 4, Issue 3, 2005, Pages 185-217

  Bacqué, Eric ^a   Barrière, Jean Claude ^a   Berthaud, Nadine ^a  

^a SANOFI   (France)

Author keywords

Antibacterial; Pristinamycins; Ribosome; Semi synthesis; Streptogramins; Structure activity relationships; Synergy

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; CLARITHROMYCIN; DALFOPRISTIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GENTAMICIN; GLYCOPEPTIDE; LINCOSAMIDE; MACROLIDE; MIKAMYCIN B; NEW DRUG; OXACILLIN; PENICILLIN G; PRISTINAMYCIN; QUINUPRISTIN; RPR 131166; RPR 132493; RPR 132552; RPR 202868; STREPTOGRAMIN; TEICOPLANIN; UNCLASSIFIED DRUG; VANCOMYCIN; VIRGINIAMYCIN;

ANTIBACTERIAL ACTIVITY; BACTERIAL INFECTION; BACTERIAL STRAIN; DOSE RESPONSE; DRUG DESIGN; DRUG METABOLISM; DRUG MIXTURE; DRUG POTENCY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; REVIEW; SEPTICEMIA; STRUCTURE ACTIVITY RELATION;

EID: 22144483423     PISSN: 15680126     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568012054368128     Document Type: Review

References (43)

1. Bax, R.; Mullan, N.; Verhoef, J. Int. J. Antimicrob. Agents, 2000, 16, 51.
2. b) Setti, E.L.; Quattrochio, L.; Micetich, R.G. Drugs Future, 1997, 22, 271.
3. c) Chu, D.T.W.; Plattner, J.J.; Katz, L. J. Med. Chem., 1996, 39, 3853.
4. Hiramatsu, K.; Hanaki, H.; Ino, T.; Yabuta, K.; Oguri, T.; Tenover, F.C. J. Antimicrob Chemother., 1997, 40, 135.
5. b) Hiramatsu, K.; Aritaka, N.; Hanaki, H.; Kawazaki, S.; Hosada, Y.; Hori, S.; Fukuschi Kobeyashi, I. Lancet, 1997, 350, 1670.
6. c) Pearson, H. Nature, 2002, 418, 469.
7. Arthur, M.; Reynolds, P.; Courvalin, P. Trends Microbiol., 1996, 401.
8. Paris, J.M.; Barrière, J.C.; Smith, C.; Bost, P.E. The Chemistry of Pristinamycins in Recent Progress In The Chemical synthesis of Antibiotics, ed. Lukacs G.and Ohno M. Springer Verlag: Berlin, Heidelberg, New York, 1991; pp 183-248.
9. Loncle, V.; Casetta, A.; Buu-Hoï, A.; El Solh, N. Antimicrob. Agents Chemother., 1993, 37, 2159.
10. Vasquez, D. In Antibiotics; Corcoran, J. N.; Hahn, F. E. (Eds), Springer Verlag: Berlin, Heidelberg, New York, 1975; Vol. III, pp 521-534.
11. Barrière, J.C.; Bouanchaud, D.H.; Paris, J.M.; Rolin, O.; Harris, N.V.; Smith C. J. Antimicrob. Chemother., 1992, 30 (suppl.A), 1.
12. Barrière, J.C.; Paris, J.M. Drugs of the Future, 1993, 18 (9), 833.
13. Barrière, J.C.; Bouanchaud, D.; Desnottes, J.F.; Paris, J.M. Expert Opinion Invest. Drugs, 1994, 3 (2), 115.
14. Presented at the 41st ICAAC (Chicago, 2001): Posters F-359 to F-362.
15. Barrière, J.C.; Berthaud, N.; Beyer, D.; Dutka-Malen, S.; Paris, J.M.; Desnottes J.F. Curr. Pharm. Des., 1998, 4, 155.
16. Kröhnke, F. Synthesis, 1976, 1.
17. Kröhnke, F.; Chem. Ber., 1935, 68, 1177.
18. Desmazeau, P.; Doerflinger, G.; Ribeill, Y.; Bacqué, E.; Barrière, J.C.; Dutruc-Rosset, G.; Puchault, G. WO99/43699.
19. Bacqué, E.; Barrière, J.C.; Doerflinger, G.; Dutruc-Rosset, G.; Pantel, G. WO01/10895.
20. Commercon, A.; Bouchard, H.; Ribeill, Y.; Bacqué, E.; Ronan, B. Barrière, J.C.; Puchault, G.; Terrier, C. WO 99/05165.
21. Ronan, B.; Bacqué, E.; Barrière, J.C.; Sablé, S. Tetrahedron, 2003, 59, 2929.
22. Desmazeau, P.; Ronan, B.; Bacqué, E.; Barrière, J.C. WO02/50083.
23. Achard, D.; Bacqué, E.; Barrière, J.C.; Bouquerel, J.; Desmazeau, P.; Grisoni, S.; Leconte, J.P.; Ribeill, Y.; Ronan, B. WO01/02427.
24. Desmazeau, P.; Ronan, B.; Bacqué, E.; Barrière, J.C. WO02/50084.
25. 50 values, corresponding to the concentration, expressed in μM, at which 50% of the cell-free poly(Phe) synthesis was blocked. See also ref. [22] for more details.
26. The ribosome, structure, function and evolution, ed. Hill W. Dahlberg, A.; E.; Garrett, R.A.; Moore, P. B.; Schlessinger, D.; Warner, J.R. American Society for Microbiology: Washington, D.C., 1990, pp. 56-70.
27. Di Giambattista, M.; Engelborghs, Y.; Nyssen, E.; Clays, K.; Cocito, C. Biochemistry, 1991,7277.
28. Aumercier, M.; Boukallab, S.; Capmau, M.L.; Le Goffic, F. J. Antimicrob. Chemother., 1986, 39, 9.
29. m of 2.5μM.
30. a) Garraffo, R.; Monnier, B.; Lapalus P.; Duplay, H. Med. Sci. Res., 1987, 15, 461.
31. b) Ballow, C.H.; Chevalier, P.J.; Geary, W.J.; Rey, J.V.; Montay, G.; Sanderink, G. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Volume 38, 1998, 24
32. c) Stamatakis M.K.; Richards J.G. The Annals of Pharmacotherapy, 1997, 31, 576.
33. a) Phung-Ba, V.; Warnery, A.; D. Scherman, D.; Wils, P. Eur. J. Pharmacol., 1995, 288, 187.
34. b) Thyss, A.; Milano, G.; Renée, N.; Cassuto-Viguier, E.; Jambou, P.; Soler, C. J. National Cancer Institute, 1993, 85, 582.
35. 4 colony-forming units (cfu) of each strain tested to plates. Inoculated plates were incubated at 37 °C in conditions appropriate to the bacterial species studied. After incubation, the minimal inhibitory concentration (MIC) was defined as the lowest concentration in mg/l that completely inhibited the growth of bacteria.
36. 0 controls ≥-3).
37. 50 was defined as the dose that protected 50% of treated mice when all the controls died.
38. 50 was defined as the dose that protected 50% of treated mice from the formation of septic abscess, when all the controls had septic abscesses.
39. 8 cfu/ml) and were treated orally by the new association or subcutaneously for Synercid® twice a day for 3 days beginning 18 h after infection. Results obtained ten days after infection were expressed as the average survival time (AST) in days and were statistically analysed by the Wilcoxon test, as already described (Rolin, O.; Huet, Y.; Bouanchaud, D.H. J. Antimicrob. Chemother, 1986, 17, suppl. B, 49). The minimal effective dose (MED) was defined as the dose (mg/kg per administration) yielding an average survival time (AST) significantly longer than that of the untreated infected controls.
40. 9 cfu) were spread onto agar plates containing the drug to be tested at concentrations of 1, 2, 4 and 8 × MIC for the strain tested. The frequencies of mutation leading to resistance selected by each drug was calculated as the ratio of the number of colony forming units (cfu) growing at 1, 2, 4 or 8 × MIC after 72 h of incubation at 37°C to the number of cfu growing without antibiotic. The MICs of (5), (7), (3), erythromycin, pefloxacin, chloramphenicol and tetracycline were determined for the selected resistant mutants (first-step mutants).
41. 2. (3) (30/70), (7) (3 strains) and (5) (strain Rob.) were tested at concentrations of 1, 2 and 4 × MIC. Clarithromycin (strain Rob.) and vancomycin (strains AS 5155 and AS TAT 2470) at concentrations of 1, 2 and 4 × MIC, were studied as reference compounds under the same experimental conditions. At intervals (1, 2, 3 and 4 h), three aliquots of cells were removed and disrupted by sonication. Bacteria released from ruptured cells were enumerated by dilution and plating.
42. 0+60h.
43. 10 cfu/lung was considered to reflect in vivo bactericidal activity based on an internal convention. See Berthaud, N.; Montay, G.; Conard, B.J.; Desnottes, J.F. J. Antimicrob. Chemother, 1995, 36, 365.